Pharma Capital

Alliance Pharma updates on Diclectin

“Whilst this is disappointing news, this will have no material impact on the company's expected near-term results.”
drugs research
Diclectin in-licenced from Duchesnay Inc for the UK in 2015

Alliance Pharma PLC (LON:APH) on Friday told investors that the UK healthcare regulator has not approved a marketing authorisation submission for Diclectin.

The product is a treatment for nausea and vomiting during pregnancy. It was in-licenced from Duchesnay Inc for the UK in 2015 and for a further nine European territories in 2016, and £1.5mln was paid to Duchesnay for all territories.

“Whilst this is disappointing news, this will have no material impact on the company's expected near-term results,” the company said in a note.

The company’s comments were echoed by finnCap analyst Mark Brewer who, in a note, said: “The announcement late on Friday that the UK’s regulator (MHRA) has not approved Diclectin for the treatment of nausea and vomiting of pregnancy (NVP) is clearly a disappointment, although not detrimental to near-term forecasts given the stronger than expected interim trading update.”

View full APH profile

Alliance Pharma plc Timeline

View All

Related Articles

Cattle-herd-(Resized).jpg
If UniBio’s plans come to fruition it won’t be too long before the company orchestrates a major adjustment to the food-chain.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.